The main competitiveness of NKCL Bio Group Inc. is the Automated Culture System of NK immune cell.
With the Automated Culture System that conforms to GMP standards, to be run by artificial intelligence, the system finds culture environments optimized for personalized culture of NK cell by itself, replacing the existing advanced manpower and improving production efficiency by more than 100 times.
In addition, NKCL Bio Group Inc. provides a ‘Personalized Immune Care Platform’ that covers the overall health promotion field, from treatment and improvement to various immune-enhancing products and programs.
Through differentiated technological competitiveness such as “Targeted Therapy and Automated Culture System”, they are advancing from the global immuno-oncology market worth 100 billion dollars to the anti-aging and beauty market.
In addition, in May 2023, they succeeded in commercializing the Automatic Culture System (ACS) for a single person, and started distributing the ACS in the domestic NK cell treatment market.